---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-147093"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2024-05-24T23:59:59+00:00"
generated_at: "2026-06-01T08:44:51.882321+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Therapeutics stockholders elect David Kirn as Class I director and ratify PwC as auditor

## Summary
- David Kirn, M.D. elected as Class I director with 35,630,613 votes for, 7,849,441 withheld, and 1,574,659 broker non-votes.
- Ratification of PricewaterhouseCoopers LLP as independent auditor for FY2024: 45,032,000 for, 21,052 against, 1,661 abstain.
- Annual Meeting held on May 21, 2024; 45,054,713 of 51,157,472 outstanding shares voted.

## SEC filing metadata
- accession: 0001193125-24-147093
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2024-05-24T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312524147093/0001193125-24-147093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312524147093/d649174d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-147093
- JSON: https://secwatch.observer/filing/0001193125-24-147093.json
- Plain text: https://secwatch.observer/filing/0001193125-24-147093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.